AuntMinnie

MAY 8, 2024

Three clinical issues that may arise with theranostics treatments will require special provisions, including spot imaging, according to insights shared during the 124th annual meeting of the American Roentgen Ray Society (ARRS) in Boston. Extravasations Extravasations, in particular, are of interest to the U.S.

Radiopharmaceuticals 75

Radiopharmaceuticals Nuclear Medicine Radiation Hospital 75

Imaging Technology

FEBRUARY 21, 2024

milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1

Clinic 89

Clinic Radiopharmaceuticals Nuclear Medicine Hospital 89

AuntMinnie

JULY 12, 2024

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Reshaping the hospital's nuclear medicine and radiopharmaceutical strategy toward theranostics involves intensive and inclusive planning, Beyder explained at SNMMI.

Nuclear Medicine 105

Nuclear Medicine Radiation Oncology Radiopharmaceuticals Radiation 105

AuntMinnie

JUNE 11, 2024

TORONTO – The radiopharmaceutical Pluvicto improves progression-free survival in patients with metastatic prostate cancer who haven’t undergone taxane therapy, according to research presented at the SNMMI meeting. Oliver Sartor, MD The study, which was awarded SNMMI’s Abstract of the Year award, shared data from the phase III PSMAfore trial.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiograph Radiographer 122

AuntMinnie

MARCH 26, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 122

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 122

AuntMinnie

JUNE 20, 2024

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

Nuclear Medicine 52

Nuclear Medicine Radiopharmaceuticals Radiation Health Science 52